The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

Gilead Sciences recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its groundbreaking HIV treatments, stands at a critical juncture as it navigates a changing landscape in the ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).